I2TC34 Stock Overview
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Intra-Cellular Therapies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$49.53 |
| 52 Week High | US$49.53 |
| 52 Week Low | US$48.74 |
| Beta | 1.03 |
| 1 Month Change | 0% |
| 3 Month Change | 1.62% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 1.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| I2TC34 | BR Pharmaceuticals | BR Market | |
|---|---|---|---|
| 7D | 0% | 1.9% | 0.9% |
| 1Y | n/a | -16.8% | 15.0% |
Return vs Industry: Insufficient data to determine how I2TC34 performed against the BR Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how I2TC34 performed against the BR Market.
Price Volatility
| I2TC34 volatility | |
|---|---|
| I2TC34 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 8.8% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: I2TC34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine I2TC34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 561 | Sharon Mates | www.intracellulartherapies.com |
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications.
Intra-Cellular Therapies, Inc. Fundamentals Summary
| I2TC34 fundamental statistics | |
|---|---|
| Market cap | R$23.39b |
| Earnings (TTM) | -R$924.18m |
| Revenue (TTM) | R$1.83b |
12.8x
P/S Ratio-25.3x
P/E RatioIs I2TC34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| I2TC34 income statement (TTM) | |
|---|---|
| Revenue | US$365.84m |
| Cost of Revenue | US$181.51m |
| Gross Profit | US$184.33m |
| Other Expenses | US$368.70m |
| Earnings | -US$184.37m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Nov 02, 2023
| Earnings per share (EPS) | -1.92 |
| Gross Margin | 50.39% |
| Net Profit Margin | -50.40% |
| Debt/Equity Ratio | 0% |
How did I2TC34 perform over the long term?
See historical performance and comparison